メトフォーミン投与のための光反応性キュマリン機能化されたナノゲル
Hend A M Abdelmohsen1, David L Rochester2, Algy Kazlauciunas3
1Department of Chemistry, Faculty of Science and Technology, Lancaster University, Lancaster, Lancashire LA1 4YB, UK; Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, Lancashire LA1 4YW, UK; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Ain Shams University, African Union Organization Street, Abbassia, Cairo 11566, Egypt.
International journal of pharmaceutics
|August 26, 2025
まとめ
光に反応するナノゲル系が,角膜新血管化を治療するためにメトホルミンを投与します. この最小侵襲的なアプローチは重度の眼疾患の繰り返し注射の代替として有望です.
科学分野:
- 眼科について
- 材料科学
- ナノテクノロジー
背景:
- 角膜新血管化は治療の選択肢が限られている重症な眼疾患です.
- 現在の治療は 反血管新生薬の注射を繰り返し行うことで 重要な副作用が生じます
研究 の 目的:
- 光に反応するナノゲルベースの薬剤投与システムを開発し,角膜新血管化を治療する.
- コントロールされた薬剤の放出のために光分解性クマリン-メトホルミン結合物を利用する.
主な方法:
- サイズ (197-226 nm) と電気的安定性を最適化して 18 種類のナノゲル製剤を設計・製造した.
- 薬物の負荷 (≈71 - 78 μg/ mg) と放出効率のための2つの最適製剤 (CM9とCM15) を特徴付けました.
- HUVECモデルを用いて,メトホルミンの放出と血管新生抑制効果を in vitro で評価した.
主要な成果:
- 2つの安定したナノゲル製剤 (CM9とCM15) が高収量で成功しました.
- 光刺激で効率的な薬物の負荷と最大92%のメトフォーミン放出を達成した.
- 光誘発メトホルミンの放出により,新しい血管の増殖を抑制することが実証された.
結論:
- 最低侵襲性で光に反応する ナノゲルシステムを開発しました
- この光分解性薬剤放出システムは 角膜新血管化などの眼疾患の治療に 潜在力を示しています
- 重度の眼疾患の管理のための新しい治療戦略の開発を進める.
関連する概念動画
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...